Document:

Exhibit 4.7

 

DESCRIPTION OF THE REGISTRANT’S
SECURITIES

REGISTERED PURSUANT TO SECTION 12 OF
THE

SECURITIES EXCHANGE ACT OF 1934

 

As of December 31, 2019, ADMA Biologics,
Inc. (the “Corporation,” “we,” or “our”) had one class of securities registered under Section
12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”): our common stock, $0.0001 par value per
share (the “Common Stock”).

 

The Company is authorized to issue 160,000,000
shares of capital stock, divided into two classes consisting of (i) 150,000,000 shares of Common Stock, and (ii) 10,000,000 shares
of preferred stock, $0.0001 par value per share (“Preferred Stock”).

 

DESCRIPTION OF COMMON STOCK

 

The following description of our Common Stock is a summary,
does not purport to be complete and is subject to the provisions of our Second Amended and Restated Certificate of Incorporation
(the “Certificate of Incorporation”) and our Amended and Restated Bylaws (the “Bylaws”). For the complete
terms of our Common Stock, please refer to our Certificate of Incorporation and our Bylaws.

 

General

 

The Common Stock is not redeemable, and has no subscription
or conversion rights. The Common Stock does not have any sinking fund provisions. Holders of Common Stock do not have cumulative
or preemptive rights.

 

Voting

 

Holders of Common Stock are entitled to one vote per share on
all matters on which stockholders are generally entitled to vote. Holders of a majority of the outstanding shares of Common Stock
constitute a quorum at a meeting of stockholders for the transaction of any business. Directors are elected by a plurality of the
votes of the shares present in person or represented by proxy at the meeting and entitled to vote on the election of directors.
Any other action is authorized by a majority of the votes cast, except where the Delaware General Corporation Law (“DGCL”)
prescribes a different percentage of votes or a different exercise of voting power.

 

Dividends

 

Holders of our Common Stock are entitled to receive ratably
such dividends, if any, as may be declared by our Board of Directors out of funds legally available therefor, subject to any preferential
dividend rights for our outstanding Preferred Stock.

 

Distributions upon Dissolution, Liquidation or Winding Up

 

Upon a liquidation, dissolution or windup of the Company, subject
to the rights, if any, of holders of any outstanding series of Preferred Stock that may be issued, holders of Common Stock shall
be entitled to receive the assets of the Company available for distribution to its stockholders ratably in proportion to the number
of shares of Common Stock held by them.

 

Delaware Anti-Takeover Law

 

The Company is subject to the provisions of Section 203 of the
DGCL. Section 203 prohibits publicly held Delaware corporations from engaging in a “business combination” with an “interested
stockholder” for a period of three years after the date of the transaction in which the person became an interested stockholder,
unless the business combination is approved in a prescribed manner. A “business combination” includes mergers, asset
sales and other transactions resulting in a financial benefit to the interested stockholder. Subject to certain exceptions, an
“interested stockholder” is a person who, together with affiliates and associates, owns, or within three years did
own, 15% or more of the corporation’s voting stock. These provisions could have the effect of delaying, deferring or preventing
a change of control of the Company or reducing the price that certain investors might be willing to pay in the future for shares
of the Company’s stock.

 

    

    

    

 

Staggered Board; Removal of Directors; Certificate of Incorporation

 

The Company’s Certificate of Incorporation divides the
Company’s Board into three classes with staggered three-year terms. Only one class of directors will be elected at each annual
meeting of the Company’s stockholders, with the other classes continuing for the remainder of their respective three year
terms. Except as the DGCL may otherwise require, any newly created directorships or vacancies on the Board may be filled only by
the Board, but subject to the rights of holders of any series of Preferred Stock.

 

The Company’s Certificate of Incorporation provides that
(i) all stockholder actions must be effected at a duly called meeting of the stockholders and (ii) stockholders may not adopt actions
by written consent without a meeting.

 

The combination of these provisions will make it more difficult
for the Company’s existing stockholders to replace the Board as well as for another party to obtain control of the Company
by replacing members of the Board. Since the Board has the power to retain and discharge the officers, these provisions could also
make it more difficult for existing stockholders or another party to effect a change in management. In addition, the authorization
of undesignated Preferred Stock makes it possible for the Board to issue Preferred Stock with voting or other rights or preferences
that could impede any attempt to effect a change of control of the Company.

 

Registration Rights

 

In connection with our acquisition of certain assets of Biotest
Pharmaceuticals Corporation (“BPC”) in 2017 (the “Biotest Transaction”), we entered into a registration
rights agreement with BPC pursuant to which BPC, or its transferee, or its affiliate(s) have, among other things, certain registration
rights under the Securities Act of 1933, as amended, with respect to its shares of our Common Stock, subject to certain transfer
restrictions. In July 2018, BPC agreed to transfer its remaining shares of Common Stock to The Biotest Divestiture Trust (the “Biotest
Trust”). In connection with the transfer of shares, the Biotest Trust has agreed to be bound by all obligations of, and will
have all of the remaining rights of BPC under the aforementioned registration rights agreement.

 

Transfer Agent

 

Continental Stock Transfer & Trust Company, 1 State Street
30th Floor, New York, New York, serves as the transfer agent and registrar for the Company’s stock.

 

Stock Exchange Listing

 

Our Common Stock is traded on the Nasdaq Stock Market under
the symbol “ADMA.”Exhibit 10.25

 

AMENDMENT I TO THE AMENDED AND RESTATED
AGREEMENT

FOR SERVICES BETWEEN ADMA BIOLOGICS, INC. AND ARETH LLC

 

This Amendment,
made as of the 25th day of September, 2017 (“Effective Date”) by and ADMA BIOLOGICS, a Delaware Corporation
located at 465 Route 17 South, Ramsey, NJ 07446 (“ADMA”) and ARETH LLC, a New Jersey limited liability corporation
with its principal place of business at 465 Route 17 South, Ramsey, NJ 07446 (“ARETH”), ADMA and ARETH may be
collectively referred to herein as the “Parties.”

 

WITNESSETH

 

WHEREAS,
the Parties entered into an Amended and Restated Agreement for Services with an effective date of January 1, 2016;

 

WHEREAS,
the Parties intend to amend the Amended and Restated Agreement for Services in the manner stated herein effective the September 25,
2017;

 

NOW THEREFORE,
in consideration of the foregoing and the mutual covenants and agreements herein contained, and for other good and valuable consideration,
the receipt and sufficiency of which is hereby acknowledged, the Parties hereto agree to amend the Amended and Restated Agreement
for Services as follows:

 

		1.	Provision 1 of Exhibit A — Compensation Rates shall be deleted in its entirety and replaced
with the following language:

 

“Rent (base) includes —
All furniture, desks, offices, cubicles, conference room use (existing space), lunch room/ kitchen, warehouse use, parking —
12,000 sq. ft. effective October 1, 2017 through September 30, 2018 at a rate of $10.00 per square foot.

 

		2.	Provision 3 of Exhibit A - Compensation Rates shall be deleted in its entirety and replaced
with the following language:

 

“All additional expenses
incurred by the building tenants such as, but not limited to:

 

		·	Office repair and maintenance, snow removal, landscaping, HVAC repair, etc. will be charged to
ADMA at a rate equal to the amount of space utilized in the building.

 

Effective October 1, 2017
through September 30, 2018 the rate is 30 %

 

Effective October 1, 2017
through September 30, 2018 rent will be calculated at 12,000 sq. ft. unless the actual amount of space increases, at ADMA’s
option. [12,000 * $10 per square foot = $12,000/12 months = $10,000 per month]

 

The Compensation Rates will be
re-evaluated and re-negotiated no later than September 30, 2018.

 

    

    

    

 

Except as
hereby modified, the Amended and Restated Agreement for Services shall remain in full force and effect and is hereby expressly
approved, ratified, and confirmed.

 

IN WITNESS
WHEREOF, the parties hereto have executed this Agreement to be effective as of the date first above written.

 

	ARETH LLC:	 	ADMA BIOLOGICS:	 
	 	 	 	 	 	 
	By:	/s/ Jerrold Grossman	 	By:	/s/ Adam S. Grossman	 
	Title:	Manager	 	Title:	President and CEO	 

 

2Exhibit 10.26

 

AMENDMENT 2 TO THE AMENDED AND RESTATED
AGREEMENT

FOR SERVICES BETWEEN ADMA BIOLOGICS, INC. AND ARETH LLC

 

This Amendment 2
(“Amendment 2”) to the Amended and Restated Agreement for Services between ADMA Biologics, Inc.,
a Delaware corporation (“ADMA”), and Areth LLC, a New Jersey limited liability company (“Areth”),
is effective as of September 27, 2018. ADMA and Areth are also referred to herein individually as a “Party”
and collectively as the “Parties”.

 

WITNESSETH

 

WHEREAS,
the Parties entered into an Amended and Restated Agreement for Services with an effective date of January 1, 2016, as amended
on September 25, 2017 (the “Agreement”); and

 

WHEREAS,
the Parties desire to further amend the Agreement to amend the Agreement in the manner stated herein.

 

NOW,
THEREFORE, in consideration of the foregoing and the mutual covenants and agreements herein contained, and for other good
and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties hereto agree to amend the
Agreement as follows:

 

		1.	Provision 1 of Exhibit A — Compensation Rates shall be deleted in its entirety and replaced
with the following language:

 

“Rent (base) includes —
All furniture, desks, offices, cubicles, conference room use (existing space), lunch room/kitchen, warehouse use, parking —
12,000 sq. ft. effective October 1, 2018 through September 30, 2019 at a rate of $10.00 per square foot.

 

		2.	Provision 3 of Exhibit A — Compensation Rates shall be deleted in its entirety and replaced
with the following language:

 

“All additional expenses
incurred by the building tenants such as, but not limited to:

 

		·	Office repair and maintenance, snow removal, landscaping, HVAC repair, etc. will be charged to
ADMA at a rate equal to the amount of space utilized in the building.

 

Effective October 1, 2018
through September 30, 2019, the rate is 30%.

 

Effective October 1, 2018
through September 30, 2019, rent will be calculated at 12,000 sq. ft. unless the actual amount of space increases, at ADMA’s
option. [12,000 * $10 per square foot = $12,000/12 months = $10,000 per month]

 

The Compensation Rates will be
re-evaluated and re-negotiated no later than September 30, 2019.

 

    

    

    

 

Miscellaneous:

 

Except as expressly provided herein, all
terms and conditions set forth in the Agreement remain unchanged and continue in full force and effect.

 

This Amendment 2 and the Agreement
embody the entire agreement and understanding between the Parties hereto with respect to the subject matter hereof and supersede
all prior agreements and understandings relating to the subject matter hereof.

 

This Amendment 2 may be executed in
any number of counterparts, each of which shall be deemed an original but all of which together shall constitute one and the same
single document, and any such counterpart containing an electronically scanned or facsimile signature will have the same effect
as original manual signatures.

 

    2

    

    

 

IN WITNESS
WHEREOF, the Parties hereby have caused this Amendment 2 to the Agreement to be executed, and the persons signing below
warrant that they are duly authorized to sign for and on behalf of their respective Parties.

 

	ADMA Biologics, Inc.	 	Areth LLC	 
	 	 	 	 
	By:	/s/ Brian Lenz	 	By:	/s/ Adam Grossman	 
	Name: 	Brian Lenz	 	Name: 	Adam Grossman	 
	Title:	EVP CFO	 	Title:	President and CEO	 
	Date:	October 18, 2018	 	Date:	October 18, 2018	 

 

3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00306-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00306-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00306-of-00352.parquet"}]]